# US 2026/0216135 A1 · Antiviral pharmaceutical composition and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216135 A1
- Document ID: US20260216135A1
- Status: Published application
- Kind: A1
- Application number: 19/148,249
- Filed: 2024-01-15
- Published: 2026-07-30
- Earliest claimed: 2023-01-16
- Applicants: Hainan Simcere Pharmaceutical Co., Ltd.
- Inventors: Tao PENG; Ying TAN; Xiaoxue LEI; Lei ZHANG
- Web page: https://patentgrep.com/patent/US20260216135A1

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are an oral pharmaceutical composition containing a spiro compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the oral pharmaceutical composition, a combined product containing the oral pharmaceutical composition and another antiviral drug, and the use of the oral pharmaceutical composition and the combined product against viral infections and in the treatment or prevention of related diseases caused by viral infections.

## Claims

### Claim 1

An oral pharmaceutical composition, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof:

### Claim 2 (depends on 1)

The oral pharmaceutical composition according to claim 1, wherein the oral pharmaceutical composition is in the form of a tablet, a capsule, a pill, a granule, a powder, an emulsion, a solution, or a suspension.

### Claim 3 (depends on 1)

The oral pharmaceutical composition according to claim 1, further comprising a disintegrant.

### Claim 4 (depends on 3)

The oral pharmaceutical composition according to claim 3, wherein the disintegrant is selected from one or more of low-substituted hydroxypropyl cellulose, carboxymethylcellulose calcium, crospovidone, dry starch, sodium carboxymethyl starch, and croscarmellose sodium, or the disintegrant is selected from one or more of low-substituted hydroxypropyl cellulose, crospovidone, and croscarmellose sodium, or the disintegrant is croscarmellose sodium.

### Claim 5 (depends on 1)

The oral pharmaceutical composition according to claim 1, further comprising a filler.

### Claim 6 (depends on 5)

The oral pharmaceutical composition according to claim 5, wherein the filler is selected from one or more of microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, calcium sulfate dihydrate, lactose, sucrose, dextrin, sorbitol, starch or a derivative thereof, mannitol, xylitol, and fructose, or the filler is selected from one or more of microcrystalline cellulose, lactose, dextrin, and starch, or the filler is selected from one or more of microcrystalline cellulose and lactose, or the filler is microcrystalline cellulose and lactose.

### Claim 7 (depends on 1)

The oral pharmaceutical composition according to claim 1, further comprising a glidant.

### Claim 8 (depends on 7)

The oral pharmaceutical composition according to claim 7, wherein the glidant is selected from one or more of colloidal silicon dioxide, talc, and wheat starch, or the glidant is selected from one or more of colloidal silicon dioxide, talc, and wheat starch, or the glidant is selected from one or more of colloidal silicon dioxide and talc, or the glidant is colloidal silicon dioxide.

### Claim 9 (depends on 1)

The oral pharmaceutical composition according to claim 1, further comprising a lubricant.

### Claim 10 (depends on 9)

The oral pharmaceutical composition according to claim 9, wherein the lubricant is selected from one or more of magnesium stearate, stearic acid, calcium stearate, zinc stearate, sodium stearyl fumarate, liquid paraffin, polyethylene glycol, sodium dodecyl sulfate, and hydrogenated vegetable oil, or the lubricant is selected from one or more of magnesium stearate, stearic acid, calcium stearate, and sodium stearyl fumarate, or the lubricant is sodium stearyl fumarate.

### Claim 11 (depends on 1)

The oral pharmaceutical composition according to claim 1, comprising the compound of formula (I) or the pharmaceutically acceptable salt thereof, a disintegrant, a filler, a glidant, and a lubricant.

### Claim 12 (depends on 11)

The oral pharmaceutical composition according to claim 11, wherein the disintegrant is croscarmellose sodium, the filler is microcrystalline cellulose and lactose monohydrate, the glidant is colloidal silicon dioxide, and the lubricant is sodium stearyl fumarate.

### Claim 13 (depends on 1)

The oral pharmaceutical composition according to claim 1, further comprising a coating agent, or further comprising a gastric-soluble film coating agent, wherein preferably, the coating agent comprises hydroxypropyl methylcellulose, iron oxide red, polyethylene glycol, and titanium dioxide.

### Claim 14 (depends on 1)

A combination product, comprising: (1) the oral pharmaceutical composition according to claim 1, and (2) another antiviral drug, or another anti-coronavirus and/or picornavirus drug, or ritonavir.

### Claim 15

(canceled)

### Claim 16 (depends on 11)

A combination product, comprising: (1) the oral pharmaceutical composition according to claim 11, and (2) another antiviral drug, or another anti-coronavirus and/or picornavirus drug, or ritonavir.

### Claim 17 (depends on 1)

A method for treating a related disease caused by infection with a coronavirus and/or a picornavirus, comprising administering to a mammal, preferably a human, in need of the treatment a therapeutically effective amount of the oral pharmaceutical composition according to claim 1.

### Claim 18 (depends on 11)

A method for treating a related disease caused by infection with a coronavirus and/or a picornavirus, comprising administering to a mammal, preferably a human, in need of the treatment a therapeutically effective amount of the oral pharmaceutical composition according to claim 11.

### Claim 19 (depends on 14)

A method for treating a related disease caused by infection with a coronavirus and/or a picornavirus, comprising administering to a mammal, preferably a human, in need of the treatment a therapeutically effective amount of the combination product according to claim 14.

### Claim 20 (depends on 16)

A method for treating a related disease caused by infection with a coronavirus and/or a picornavirus, comprising administering to a mammal, preferably a human, in need of the treatment a therapeutically effective amount of the combination product according to claim 16.
